CVRXHealthcare · Medical DevicesThe 7 Wall Street analysts covering CVRx, Inc. hold a median 12-month price target of $4.5 — +215.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 28 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores CVRx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (83): Smaller than most of the companies we track.
Momentum (9): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CVRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +215.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $13 → $5.00 |
| 8 Aug 2026 | Lake Street | Downgrade | Hold | — |
| 7 Aug 2026 | Lake Street | Downgrade | Hold | $14 → $3.50 |
| 14 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 14 Apr 2026 | Canaccord Genuity | Maintains | Buy | $10 |
| 13 Feb 2026 | Canaccord Genuity | Maintains | Buy | — |
| 6 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 6 Nov 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 5 Aug 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 9 May 2025 | JP Morgan | Downgrade | Underweight | — |
| 9 May 2025 | Piper Sandler | Maintains | Overweight | — |
| 8 Apr 2025 | Canaccord Genuity | Maintains | Buy | — |
| 8 Apr 2025 | Lake Street | Maintains | Buy | — |
| 5 Feb 2025 | Canaccord Genuity | Maintains | Buy | — |
| 5 Feb 2025 | Piper Sandler | Maintains | Overweight | — |
| 17 Jan 2025 | Craig-Hallum | Maintains | Buy | — |
| 14 Jan 2025 | William Blair | Upgrade | Outperform | — |
| 9 Dec 2024 | Canaccord Genuity | Maintains | Buy | — |
| 4 Nov 2024 | Craig-Hallum | Maintains | Buy | — |
| 30 Oct 2024 | Canaccord Genuity | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CVRX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, CVRx, Inc. returned −86.8% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 77% of US stocks
Cheaper than 45% of US stocks
Cheaper than 67% of US stocks
Higher than 63% of US stocks
Higher than 54% of US stocks
Higher than 95% of US stocks
Higher than 15% of US stocks
Higher than 7% of US stocks
Higher than 10% of US stocks
Higher than 15% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CVRx, Inc. has a market value of $37.7M and an enterprise value of $32.5M.
Revenue in the twelve months to 30 June 2026: $61.2M. The latest quarter grew 15.6% year on year.
Net income over the same four quarters: −$52.0M, a −84.9% net margin.
Diluted earnings per share, trailing twelve months: $−1.98.
Free cash flow in the twelve months to 30 June 2026: −$41.1M.
Trailing P/E: −0.7×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
CVRx, Inc. employs 223 people — $274K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CVRx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CVRx said it will release its third-quarter 2026 financial and operating results after market close on November 5, 2026, and host a conference call to review them at 4:30 p.m. Eastern Time that day.
Why it matters — CVRx watchers can note the date and time when the company plans to provide its quarterly results and discuss them.
CVRx announced the schedule of scientific presentations featuring its Barostim device at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026, including late-breaking data and new clinical evidence. The announcement was made on September 29, 2026.
Why it matters — The presentation of late-breaking data and new clinical evidence at a major scientific meeting could draw attention to Barostim's clinical standing within the heart failure community.
CVRx announced the appointment of John Landry as its new Chief Financial Officer. Landry brings roughly two decades of medtech and public company finance experience to the role.
Why it matters — A CVRX watcher would care because a seasoned CFO with extensive medtech and public company finance background could bring financial and strategic leadership to the company.
CVRx has secured Devoted Health Medicare Advantage coverage for its Barostim therapy, expanding reimbursement access to approximately 466,000 members across 29 states.
Why it matters — Expanded insurance coverage could widen patient access to Barostim, potentially supporting broader adoption of CVRx's therapy.
CVRx issued a statement in response to a public letter dated August 24, 2026, sent to its Board of Directors by Jorey Chernett of Pointillist Family Office. The company said its Board and leadership remain committed to acting in the best interests of all shareholders and regularly evaluate a full range of options to maximize shareholder value.
Why it matters — The shareholder letter and CVRx's public response signal an active, open engagement between the company's board and an investor, which CVRx watchers would follow for potential governance or strategic developments.
The 7 Wall Street analysts covering CVRx, Inc. have a median 12-month price target of $4.5, with estimates ranging from $3.5 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering CVRx, Inc., 3 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks CVRx, Inc. 30 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, CVRx, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +215.8% from the last close, and Ticker Nerd's factor model ranks CVRx, Inc. 30 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CVRx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.5 to $6 over the next 12 months.
CVRx, Inc. returned -86.8% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
CVRx, Inc. is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular disease.
The most recent item we track (GlobeNewsWire, 22 Oct 2026): "CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026". CVRx said it will release its third-quarter 2026 financial and operating results after market close on November 5, 2026, and host a conference call to review them at 4:30 p.m. Eastern Time that day.
CVRx, Inc. is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular disease. Its flagship product, Barostim, is an implantable therapy system that delivers electrical pulses to carotid baroreceptors to help regulate autonomic nervous system activity and support cardiovascular function. The company’s current offerings center on Baroreflex Activation Therapy, a minimally invasive treatment approach used for patients with heart failure and other cardiovascular conditions. CVRx develops, manufactures, and commercializes its products in the United States, Germany, and selected international markets through direct sales and distribution channels. Headquartered in Minneapolis, Minnesota, CVRx plays a specialized role in the medical technology market by providing device-based therapies that address complex cardiac care needs.
CEO Mr. Kevin Hykes · 223 employees · United States · https://www.barostim.com
